Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial

Breast Cancer Research and Treatment

Volumn 150, Issue 1, 2015, Pages 149-155

  Hadad, Sirwan M ^a   Coates, Philip ^b   Jordan, Lee B ^b   Dowling, Ryan J O ^c   Chang, Martin C ^d   Done, Susan J ^c   Purdie, Colin A ^b   Goodwin, Pamela J ^c   Stambolic, Vuk ^c   Moulder Thompson, Stacy ^e   Thompson, Alastair M ^f  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Dundee Cancer Centre   (United Kingdom)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MOUNT SINAI HOSPITAL   (United States)

^e Princess Margaret Hospital and Mount Sinai Hospital ^*  (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Caspase 3; Clinical trial; Insulin; Ki67; Metformin; Phospho Akt; Phospho AMPK

Indexed keywords

CASPASE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; INSULIN RECEPTOR; KI 67 ANTIGEN; METFORMIN; PROTEIN KINASE B; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ARTICLE; BLOATING; BODY MASS; BREAST CANCER; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOWN REGULATION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; TUMOR BIOPSY; UPREGULATION; ADJUVANT THERAPY; BREAST NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BIOMARKERS; BREAST NEOPLASMS; CASPASE 3; FEMALE; HUMANS; KI-67 ANTIGEN; METFORMIN; NEOADJUVANT THERAPY; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84925492210     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3307-5     Document Type: Article

References (35)

1. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503):1304–1305. doi:10.1136/bmj.38415.708634.F7
2. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32(9):1620–1625. doi:10.2337/dc08-2175
3. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52(9):1766–1777. doi:10.1007/s00125-009-1440-6
4. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E (2009) Sulphonylureas and cancer: a case-control study. Acta Diabetol 46(4):279–284. doi:10.1007/s00592-008-0083-2
5. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3(11):1451–1461. doi:10.1158/1940-6207 CAPR-10-0157
6. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29(2):254–258
7. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ (2010) Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33(2):322–326. doi:10.2337/dc09-1380
8. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH (2011) The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer J Int Cancer. doi:10.1002/ijc.26421
9. Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM (2011) Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer. doi:10.1002/cncr.26439
10. Chen TM, Lin CC, Huang PT, Wen CF (2011) Metformin associated with lower mortality in diabetic patients with early stage hepatocellular carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 26(5):858–865. doi:10.1111/j.1440-1746.2011.06664.x
11. Bo S, Ciccone G, Rosato R, Villois P, Appendino G, Ghigo E, Grassi G (2012) Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients. Diabetes Obes Metab 14(1):23–29. doi:10.1111/j.1463-1326.2011.01480.x
12. Thompson AM (2014) Molecular pathways: preclinical models and clinical trials with metformin in breast cancer. Clin Cancer Res 20(10):2508–2515. doi:10.1158/1078-0432.CCR-13-0354
13. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42–51
14. Pollak M (2010) Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res 3(9):1060–1065. doi:10.1158/1940-6207 CAPR-10-0175
15. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, Jellema G, Deharo S, Hardie DG, Pusztai L, Moulder-Thompson S, Dewar JA, Thompson AM (2011) Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat 128(3):783–794. doi:10.1007/s10549-011-1612-1
16. Hardie DG (2011) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25(18):1895–1908. doi:10.1101/gad.17420111
17. Hardie DG, Ross FA, Hawley SA (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13(4):251–262. doi:10.1038/nrm3311
18. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, Fleming S, Thompson AM (2009) Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 9:307. doi:10.1186/1471-2407-9-307
19. Zhuang Y, Miskimins WK (2008) Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3:18. doi:10.1186/1750-2187-3-18
20. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, Birnbaum MJ, Thompson CB (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18(3):283–293. doi:10.1016/j.molcel.2005.03.027
21. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66(21):10269–10273. doi:10.1158/0008-5472.CAN-06-1500
22. Hadad SM, Fleming S, Thompson AM (2008) Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol 67(1):1–7. doi:10.1016/j.critrevonc.2008.01.007
23. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126(1):215–220. doi:10.1007/s10549-010-1224-1
24. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V, Goodwin PJ (2012) Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135(3):821–830. doi:10.1007/s10549-012-2223-1
25. Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17(5):1474–1481
26. Purdie CA, Jordan LB, McCullough JB, Edwards SL, Cunningham J, Walsh M, Grant A, Pratt N, Thompson AM (2010) HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 56(6):702–707. doi:10.1111/j.1365-2559.2010.03533.x
27. Kalinsky K, Hershman DL (2012) Cracking open window of opportunity trials. J Clin Oncol 30(21):2573–2575. doi:10.1200/JCO.2012.42.3293
28. Hadad SM, Hardie DG, Appleyard V, Thompson AM (2013) Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle. Clin Transl Oncol. doi:10.1007/s12094-013-1144-8
29. Kucab JE, Lee C, Chen CS, Zhu J, Gilks CB, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn SE (2005) Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 7(5):R796–R807. doi:10.1186/bcr1294
30. Goodwin PJ, Thompson AM, Stambolic V (2012) Diabetes, metformin, and breast cancer: lilac time? Journal of Clin Oncol 30(23):2812–2814. doi:10.1200/JCO.2012.42.3319
31. Hawley SA, Ross FA, Chevtzoff C, Green KA, Evans A, Fogarty S, Towler MC, Brown LJ, Ogunbayo OA, Evans AM, Hardie DG (2010) Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 11(6):554–565. doi:10.1016/j.cmet.2010.04.001
32. Scheen AJ (1996) Clinical pharmacokinetics of metformin. Clinical Pharmacokinet 30(5):359–371
33. Mann GB, Fahey VD, Feleppa F, Buchanan MR (2005) Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 23(22):5148–5154. doi:10.1200/JCO.2005.02.076
34. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30(21):2593–2600. doi:10.1200/JCO.2011.39.3769
35. Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell’Orto P, Lazzeroni M, Serrano D, Viale G, Bonanni B (2013) The effect of metformin on apoptosis in a breast cancer presurgical trial. Br J Cancer 109(11):2792–2797. doi:10.1038/bjc.2013.657